These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 31173856)

  • 1. Akt in cancer: Mediator and more.
    Revathidevi S; Munirajan AK
    Semin Cancer Biol; 2019 Dec; 59():80-91. PubMed ID: 31173856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of PI3K/AKT in tumor-related epigenetic regulation.
    Yang Q; Jiang W; Hou P
    Semin Cancer Biol; 2019 Dec; 59():112-124. PubMed ID: 30951826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
    Iida M; Harari PM; Wheeler DL; Toulany M
    Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
    Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
    Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
    Toulany M; Rodemann HP
    Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
    Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
    Jiang W; Ji M
    Semin Cancer Biol; 2019 Dec; 59():3-22. PubMed ID: 30943434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
    Jiang BH; Liu LZ
    Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between the CK2 and AKT signaling pathways in cancer.
    Ruzzene M; Bertacchini J; Toker A; Marmiroli S
    Adv Biol Regul; 2017 May; 64():1-8. PubMed ID: 28373060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.
    Nagini S; Sophia J; Mishra R
    Semin Cancer Biol; 2019 Jun; 56():25-36. PubMed ID: 29309927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Akt in cancer for precision therapy.
    Hua H; Zhang H; Chen J; Wang J; Liu J; Jiang Y
    J Hematol Oncol; 2021 Aug; 14(1):128. PubMed ID: 34419139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/Akt signalling pathway and cancer.
    Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
    Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.
    Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A
    Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K and AKT: Unfaithful Partners in Cancer.
    Faes S; Dormond O
    Int J Mol Sci; 2015 Sep; 16(9):21138-52. PubMed ID: 26404259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.
    Cassinelli G; Zuco V; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2013; 20(15):1923-45. PubMed ID: 23410153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.